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Abstract
Background Patients with Gitelman syndrome, a hereditary
salt-wasting tubulopathy, have loss-of-function mutations in
the SLC12A3 gene coding for the thiazide-sensitive sodium
chloride co-transporter in the distal convoluted tubule. Since
the bulk of filtered phosphate is reabsorbed in the proximal
tubule, renal phosphate wasting is considered exceptional in
Gitelman syndrome.
Methods We investigated the renal handling of inorganic
phosphate in 12 unselected Italian patients affected with
Gitelman syndrome (5 females and 7 males, aged 6.0–18
years, median age 12 years) and in 12 healthy subjects
matched for gender and age (controls). The diagnosis of
Gitelman syndrome among the patients had been made
clinically and confirmed by molecular biology studies.
Results The biochemical hallmarks of Gitelman syndrome,
namely hypochloremia, hypokalemia, hypomagnesemia, in-
creased urinary excretion of sodium, chloride, potassium
and magnesium and reduced urinary excretion of calcium,
were present in the 12 patients. In addition, both the plasma
inorganic phosphate concentration (median and interquartile
range: 1.28 [1.12–1.36] vs. 1.61 [1.51–1.66)] mmol/L) and
the maximal tubular reabsorption of inorganic phosphate
(1.08 [0.99–1.22] vs. 1.41 [1.38–1.47] mmol/L) were sig-
nificantly lower (P<0.001) in Gitelman patients than in con-
trol subjects. Circulating levels of 25-hydroxyvitamin D,
intact parathyroid hormone and osteocalcin were similar in
patients and controls.
Conclusions The results of our case–control study disclose
a hitherto unrecognized tendency towards renal phosphate
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wasting with mild to moderate hypophosphatemia in
Gitelman syndrome.
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Introduction
The kidney plays a key role in the maintenance of inorganic
phosphate homeostasis [1, 2]. Since the bulk of filtered inor-
ganic phosphate is reabsorbed in the proximal tubule, renal
phosphate wasting is common in proximal renal-tubular
disorders [3].
The terms Bartter andGitelman syndrome are used to denote
a group of autosomal-recessive disorders with a unifying path-
ophysiology consisting of salt loss either by the limb of Henle
or the distal convoluted tubule. Affected patients present with
low or normal blood pressure, an activated renin–angiotensin–
aldosterone system and hypokalemia with or without concur-
rent hypomagnesemia [4, 5]. Hypophosphatemia is considered
rare in Bartter and especially in Gitelman syndrome, the most
frequent form of thementioned salt wasting disorders [6, 7].We
noticed a tendency towards low inorganic phosphate levels in
some of our Gitelman patients which led us to investigate the
renal handling of this ion in the context of a case–control study.
The results of the study indicate a counterintuitive predisposi-
tion towards renal phosphate wasting in these patients.
Patients and methods
All patients with Gitelman syndrome on regular follow-up at
the renal unit of the Division of Pediatrics, San Leopoldo
Mandic Hospital were eligible for enrollment in the trial.
Between September and November 2011, a group of 12
Italian patients from nine different families (5 females and
7 males aged 6.0–18 years, median age 12 years) who
presented for a scheduled visit and a control group of 12
healthy subjects matched for age and gender (5 females and
7 males aged 6.9–18 years, median age 11 years) entered the
study. All patients had history of frequent tetanic episodes,
muscular weakness or fatigue, and the diagnosis of Gitel-
man syndrome was based on the presence of normal or low
blood pressure, hypokalemia, hypomagnesemia, inappropri-
ate urinary excretion of chloride and magnesium, hypocal-
ciuria and normal results on renal ultrasound. In addition,
biallelic mutations in the gene encoding the thiazide-
sensitive sodium chloride co-transporter had been identified
in 11 patients (Table 1). All of the mutations have been
previously described [8–11], with the exception of those of
patient no. 11 who had a frameshift mutation disrupting
protein synthesis and a missense mutation that substitutes
for the highly conserved residue Arg871.
The study was approved by the Human Subjects Re-
search Committee of Merate–Lecco Hospital. The Gitelman
patients, who did not discontinue their medication with
potassium chloride (N011), potassium-sparing diuretics
(spironolactone, N06; amiloride, N01), indomethacin (N0
1) and magnesium (N01), and the control subjects attended
the outpatient clinic after overnight fasting and received a tap
water (sodium content <1.0 mmol/L) load of 400 mL [12].
After voiding the bladder, an approximately 2-h urine speci-
men was collected, and a mid-point blood sample was taken
with minimal stasis and without movement of the forearm
[12]. Creatinine, sodium, chloride, potassium, total calcium
and magnesium and inorganic phosphate were assessed in
both the blood and urine samples, urea, bicarbonate, 25-
Table 1 Mutations in the SLC12A3 gene, located on 16q13 chromosome, coding for the thiazide-sensitive sodium chloride co-transporter in the
distal convoluted tubule detected in 11 of the 12 patients enrolled in the study
Patient no. Family no. Nucleotide changes Predicted effects at protein level
1 I c.[2981G>A]; [506-?_742+?del] p.[Cys994Tyr]; [Val169_Gln247del]
2 II c.[2981G>A]; [2981G>A] p.[Cys994Tyr]; [Cys994Tyr]
3 III c.[1196_1202dup7bp]; [ 1424C>G] p.[Ser402*]; [Ser475Cys]
4 III c.[1196_1202dup7bp]; [ 1424C>G] p.[Ser402*]; [Ser475Cys]
5 IV c.[1196_1202dup7bp]; [1196_1202dup7bp] p.[Ser402*]; [Ser402*]
6 IV c.[1196_1202dup7bp]; [1196_1202dup7bp] p.[Ser402*]; [Ser402*]
7 V c.[ 1175C>T]; [1844C>T] p.[Thr392Ile]; [Ser615Leu]
8 V c.[ 1175C>T]; [1844C>T] p.[Thr392Ile]; [Ser615Leu]
9 VI c.[1844C>T]; [1925G>A] p.[Ser615Leu]; [Arg642His]
10 VII c.[557G>A]; [1742T>A] p.[Gly186Asp];[Met581Lys]
11 VIII c.[283delC]; [ 2612G>C] p.[Gln95Argfs*18];[ Arg871Pro]
The mutations disclosed in patients from 1 to 10 have been previously reported [8–11]. GenBank accession number NM_000339.2 is used as a
reference sequence, in which the A of ATG is number 1. Nomenclature is according to HGVS v.2
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hydroxyvitamin D, alkaline phosphatase, intact parathyroid
hormone and osteocalcin were assessed only in the blood
samples. Creatinine, urea, sodium, bicarbonate, chloride, po-
tassium, total calcium and magnesium and inorganic phos-
phate were measured on an automated auto-analyzer using
colorimetric assays or ion-selective electrodes. Intact parathy-
roid hormone was measured by a two-site radioimmunometric
assay, 25-hydroxyvitamin D using a competitive protein-
binding assay and osteocalcin by radioimmunoassay.
The glomerular filtration rate was estimated from height
and plasma creatinine [13]. The fractional urinary excretion
of sodium, chloride, potassium, calcium, magnesium and
inorganic phosphate was calculated from their plasma (PX)
or urinary (UX) level, as well as from plasma (PCr) or urinary
(UCr) creatinine as follows [12, 14]:
Ux  PCr
Px  UCr
The maximal tubular reabsorption of inorganic phos-
phate, the best means of defining the renal tubular handling
of this ion, was calculated from plasma (PPh) or urinary
(UPh) phosphate and plasma (PCr) or urinary (UCr) creatinine
as follows [12, 14]:
PPh  UPh  PCrUCr
 
Blood and urinary levels of sodium, chloride, potassium
and magnesium are age and gender-independent [15], and
the blood levels of inorganic phosphate and those of its
maximal tubular reabsorption significantly vary with age
and gender [14, 15]. Hence, the values obtained in our study
were also compared with those given in the literature [14]
and expressed as the standard deviation score (SDS). Descrip-
tive statistics are presented as median and interquartile range
(IQR), which extends from the value at the 25th percentile to
the value at the 75th percentile and includes half of the data
points. The two-tailed Wilcoxon–Mann–Whitney test for two
independent samples and simple linear regressions with the
rank correlation coefficient rs were performed for the analysis.
Significance was assumed when P<0.05.
Results
Body height and weight were significantly lower in the
group of patients affected with Gitelman syndrome than in
the control group (Table 2). Blood pressure, heart rate and
pubic hair development were not statistically different be-
tween the patients (Marshall–Tanner stage ranging from 1 to
5, median 2) and controls (Marshall-Tanner stage ranging
from 1 to 4, median 2). Apart from the biochemical hall-
marks of Gitelman syndrome, namely hypochloremia,
hypokalemia, hypomagnesemia, increased urinary excretion
of sodium, chloride, potassium and magnesium, and re-
duced urinary calcium excretion, the group of patients
was found to have some tendency towards total hyper-
calcemia. However, patients affected with Gitelman syn-
drome and control subjects did not significantly differ in
terms of plasma creatinine and urea levels, estimated
glomerular filtration rate and levels of plasma sodium
and bicarbonate, serum 25-hydroxyvitamin D, plasma
alkaline phosphatase, serum intact parathyroid hormone
and serum osteocalcin.
Both the plasma inorganic phosphate concentration and
the maximal tubular reabsorption of inorganic phosphate
were significantly lower in Gitelman patients than in control
subjects, as shown in Table 3. In contrast, the fractional
excretion of this analyte was not statistically different be-
tween the patients and controls. Figure 1 shows the relation-
ship between the maximal tubular reabsorption of inorganic
phosphate and its plasma level in individual Gitelman
patients and controls expressed as the SDS. In this figure,
the relationship between the maximal tubular reabsorption
of inorganic phosphate and its plasma level observed in
patients and in controls are compared with age- and sex-
specific reference values obtained 30 years ago in Germany.
A tendency towards age- and gender-corrected hypophos-
phatemia was noted in eight of the 12 Gitelman patients.
Plasma inorganic phosphate level and the maximal tubular
reabsorption of inorganic phosphate were not statistically
different in patients with and without potassium-sparing
diuretics.
In patients with Gitelman syndrome a significant rela-
tionship was noted between the fractional urinary excretion
of chloride and potassium, taken as independent values, and
that of inorganic phosphate, taken as dependent values
(Fig. 2). No significant relationship was noted between
circulating magnesium levels or its fractional urinary excre-
tion and the urinary excretion of inorganic phosphate, nor
between circulating bicarbonate levels and the urinary ex-
cretion of inorganic phosphate.
Discussion
The results of our case–control study in unselected Gitelman
patients reveal a hitherto unrecognized tendency towards
renal phosphate wasting with mild to moderate hypophos-
phatemia. At first glance it appears surprising that in Gitel-
man syndrome, as in Bartter syndrome, the issue of
hypophosphatemia has remained so far unrecognized with
the exception of two case reports [6, 7]. This is related, in
our opinion, to the fact that hypophosphatemia is mild and
that many central laboratories do not provide accurate age-
and sex-specific reference values.
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Table 3 Levels and renal handling of inorganic phosphate in the 12 patients affected with Gitelman syndrome and the 12 control subjectsa
Renal handling of inorganic phosphate Patients with Gitelman Syndrome Control subjects Significance
Plasma inorganic phosphate concentration
Absolute value, mmol/L 1.28 [1.12–1.36] 1.61 [1.51–1.66] P<0.001
SDSb −2.4 [−3.2 to −1.5] −0.2 [−0.5–0.1] P<0.005
Maximal tubular reabsorption of phosphate
Absolute value, mmol/L 1.08 [0.99–1.22] 1.41 [1.38–1.47] P<0.001
SDSb −2.6 [−3.0 to −1.9] −1.5 [−1.8 to −1.1] P<0.01
Fractional excretion of inorganic phosphate, 10−2 8.8 [6.8–13.8] 11.4 [8.7–12.2] NS
SDS, Standard deviation score; IQR, interquartile range
Data are presented as the median, with the IQR given in square parenthesis
a See footnotes to Table 1 for description of patient and control groups
b Calculated from data obtained in healthy German subjects (reference [14])
Table 2 Laboratory findings other than levels and renal handling of inorganic phosphate in the 12 patients affected with Gitelman syndrome and
the 12 control subjects
Clinical findings Patients with Gitelman syndromea Control subjectsb Significance
Body height, m 1.338 [1.158–1.498] 1.433 [1.365–1.528] P<0.05
Body weight, kg 31.0 [21.2–37.0] 41.8 [36.5–49.8] P<0.05
Supine blood pressure, mm Hg 110 [99–120]/60 [49–73] 113 [101–122]/66 [52–74] NS
Supine heart rate, /min 78 [66–84] 75 [64–86] NS
Plasma creatinine, μmol/L 49 [40–55] 54 [49–57] NS
Glomerular filtration rate, mL/min/1.73 m2 135 [125–144] 132 [126–138] NS
Plasma urea, mmol/L 5.0 [4.3–6.8] 5.9 [4.6–6.0] NS
Sodium
Plasma level, mmol/L 135 [134–136] 136 [135–137] NS
Fractional excretion, 10−2 0.85 [0.57–10.7] 0.59 [0.30–0.65] P<0.05
Plasma bicarbonate, mmol/L 29 [27–31] 27 [26–29] NS
Chloride
Plasma level, mmol/L 97 [95–98] 101 [100–102] P<0.001
Fractional excretion, 10−2 1.57 [1.12–2.09]c 0.55 [0.40–0.83] P<0.001
Potassium
Plasma level, mmol/L 3.0 [2.7–3.1] 4.1 [3.9–4.2] P<0.0001
Fractional excretion, 10−2 22 [15–29] 4.9 [3.1–10] P<0.001
Total calcium
Plasma level, mmol/L 2.52 [2.46–2.54] 2.41 [2.37–2.47] P<0.05
Fractional excretion, 10−2 0.17 [0.12–0.39] 0.84 [0.51–1.45] P<0.01
Total magnesium
Plasma level, mmol/L 0.69 [0.59–0.71] 0.91 [0.79–0.94] P<0.001
Fractional excretion, 10−2 4.5 [3.5–5.7] 3.2 [2.6–4.0] P<0.05
Serum 25-hydroxyvitamin D, pmol/L 79 [62–110] 79 [55–89] NS
Plasma alkaline phosphatase, U/L 241 [145–250] 241 [187–284] NS
Serum intact parathyroid hormone, pmol/L 1.6 [1.2–4.3] 3.2 [1.6–5.3] NS
Serum osteocalcin, μg/L 49 [36–70] 57 [44–90] NS
NS, Not significant
Data are presented as the median, with the interquartile range (IQR) given in square parenthesis
a Five females, seven males; aged 6.0–18, median 12 years
b Five females, 7 males; aged 6.9–18 years, median 11 years
cN011
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Gitelman syndrome, a salt-wasting tubulopathy, is caused
by mutations in the gene coding for the thiazide-sensitive
sodium chloride co-transporter [4, 5, 8–11]. This genetic
component underlies the profound homology between this
tubulopathy and subjects managed with thiazides [4, 5].
There is general agreement with regard to the effects of
thiazides on sodium and potassium balance [16, 17]. Rela-
tively little attention has been paid, however, to their effects
on phosphate homeostasis [16, 17]. Nevertheless, long-term
management with thiazides might cause a tendency towards
hyperphosphaturia and hypophosphatemia [16–18].
Circulating calcium exists in three forms, namely the
form bound to proteins, the form complexed with low-
molecular-weight anions, such as bicarbonate, and the ion-
ized form, which is the only biologically active form [1]. In
Gitelman syndrome, the amount of circulating calcium
bound to proteins or complexed to bicarbonate is increased
[19]. As a consequence, in these patients the total circulating
calcium level is, on average, slightly increased, as noted in
our study, but the level of ionized circulating calcium is
normal or slightly reduced [19].
Plasma inorganic phosphate levels are high in children,
falling remarkably during and after puberty [14, 15]. In our
healthy Italian volunteers, the plasma concentration of inor-
ganic phosphate and its maximal tubular reabsorption were
rather low when compared with the corresponding age- and
gender-matched reference values obtained more than
30 years ago in Germany [14]. These differences are likely
related to both puberty today beginning earlier than it did
30 years ago and Italian children entering puberty earlier
than German children [20].
In contrast to the regulation of calcium homeostasis, rela-
tively little is known about the renal regulation of phosphate
homeostasis [1, 2, 21–23]. Since extracellular fluid volume
expansion increases the excretion of inorganic phosphate, and
extracellular fluid volume contraction decreases it, changes in
extracellular fluid volume likely do not account for the ten-
dency towards renal phosphate wasting in a salt-wasting
K+-sparing diuretics +
K+-sparing diuretics -
Fig. 2 Relationship between the fractional urinary excretion of chlo-
ride (upper panel) and potassium (lower panel) and that of inorganic
phosphate in Gitelman patients. The relationship (dashed line) was
statistically significant in both cases. The fractional urinary excretion
of chloride was not assessed in one case. Patients with (+) and without
(−) potassium-sparing diuretics are denoted by different symbols
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Fig. 1 Relationship between the maximal tubular reabsorption of
inorganic phosphate and the corresponding plasma level in 12 Gitel-
man patients and 12 healthy subjects matched for age and gender. The
results are expressed as the standard deviation score (SDS). The shaded
area denotes the reference values obtained from the literature [9]. The
plasma inorganic phosphate concentration was normal in the 12
healthy control subjects and reduced in eight of the 12 patients.
Patients with (+) and without (−) potassium-sparing diuretics are
denoted by different symbols
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condition such as Gitelman syndrome [1, 2]. There is often a
tendency towards metabolic alkalosis in Gitelman syndrome
[4, 5]: it is recognized, however, that metabolic alkalosis,
contrary to respiratory alkalosis, does not conspicuously mod-
ulate phosphate metabolism [1, 2]. There is also an association
between hypokalemia and hypophosphatemia in either famil-
ial or thyrotoxic hypokalemic periodic paralysis, and between
hypomagnesemia and hypophosphatemia in either the treat-
ment of uncontrolled diabetes mellitus or in refeeding. In
the latter conditions, however, the electrolyte disturbances
result from their shift into cells without renal wasting [1,
2]. Prostaglandin overproduction, a recognized cause of
hyperphosphaturia [1, 2], is a constant feature in both
classic and neonatal Bartter syndrome. In contrast, Gitel-
man syndrome patients display a normal urinary excretion
of prostaglandin E2 [24]. Furthermore, our data suggest
that in Gitelman disease the tendency towards renal phos-
phate wasting is not related to an altered circulating level
of either 25-hydroxyvitamin D or parathyroid hormone.
Finally, the significant relationship between urinary chlo-
ride level and phosphate excretion noted in our Gitelman
patients might point to some phosphate reabsorption also
occurring in the distal segments of the nephron [1].
There is a tendency towards mild to moderate hypophos-
phatemia in primary hyperaldosteronism and towards hyper-
phosphatemia upon treatment with potassium-sparing
diuretics [2]. For this reason, Gitelman patients receiving
treatment with either spironolactone or amiloride were in-
cluded in our study.
Knowledge of the mechanisms that participate in renal
phosphate homeostasis has greatly improved during the
past few years following the recognition of phosphaturic
hormone fibroblastic growth factor 23 [21–23]. Many
disorders associated with low circulating levels of this
hormone are characterized by hyperphosphatemia. On the
other hand, disorders associated with high circulating
levels are characterized by hypophosphatemia [21–23].
The determination of circulating fibroblastic growth fac-
tor 23 and 1,25-dihydroxyvitamin and studies investigat-
ing the renal handling of inorganic phosphate in Bartter
syndrome should therefore be useful in ascertaining the
mechanisms underlying hypophosphatemia in Gitelman
syndrome.
Conflict of interest None declared.
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